MRNA

mRNA-1273

COVID-19 Vaccine

Stage (next event)

Expected Date

FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) meeting

December 17, 2020

Catalyst Info & Data Links

TITLE: mRNA-1273 COVID-19 Vaccine Phase 3 interim data

  • Phase 1 - ClinicalTrial.gov (NCT04283461): Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19)

  • Phase 2 - ClinicalTrial.gov (NCT04405076): Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and Older

  • Phase 3 - ClinicalTrial.gov (NCT04470427): A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19


WHAT IS THE NEXT CATALYST EVENT?


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?  


PRIOR DATA

PRESS RELEASES/EVENTS

MECHANISM OF ACTION / RATIONALE

  • mRNA-1273 is an mRNA vaccine against SARS-CoV-2 encoding for a prefusion stabilized form of the Spike (S) protein, which was selected by Moderna in collaboration with investigators from Vaccine Research Center (VRC) at the National Institute of Allergy and Infectious Diseases (NIAID), a part of the NIH.

Updated by HC

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See what the community is saying - click to see full post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon